Development of formulations of sorafenib tosylate for improved biopharmaceutical potential

• At: Glasgow (Scotland) (2018)
• Type: Poster
• Poster code: POS-FDP-016
• By: SHARMA, Teenu (Panjab University, University institute of Pharmaceutical sciences)
• Co-author(s): Teenu Sharma: University institute of Pharmaceutical sciences, Panjab University, Chandigarh, India
  Atul Jain: UGC-CoE ANNN, Panjab University, Chandigarh, India
  O P Katare: University institute of Pharmaceutical sciences, Panjab University, Chandigarh, India
  Bhupinder Singh: UGC-CoE ANNN, University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh, India
  
• Abstract:

  Background

  Sorafenib tosylate, BCS class II anticancer drug, exhibits low oral bioavailability (8%) ostensibly owing to poor aqueous solubility, high first-pass effect and P-gp efflux. 

  Methods

  The patient-centric quality target product profile (QTPP) and critical quality attributes (CQAs) were earmarked. Ishikawa Fish-bone diagram was constructed
  ..

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login